Literature DB >> 9733503

Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

M S Kramer1, N Cutler, J Feighner, R Shrivastava, J Carman, J J Sramek, S A Reines, G Liu, D Snavely, E Wyatt-Knowles, J J Hale, S G Mills, M MacCoss, C J Swain, T Harrison, R G Hill, F Hefti, E M Scolnick, M A Cascieri, G G Chicchi, S Sadowski, A R Williams, L Hewson, D Smith, E J Carlson, R J Hargreaves, N M Rupniak.   

Abstract

The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs. In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently observed. In preclinical studies, substance P antagonists did not interact with monoamine systems in the manner seen with established antidepressant drugs. These findings suggest that substance P may play an important role in psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733503     DOI: 10.1126/science.281.5383.1640

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  177 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  [New developments in pharmacotherapy of depression].

Authors:  R Rupprecht; Th C Baghai; H-J Möller
Journal:  Nervenarzt       Date:  2003-05-10       Impact factor: 1.214

Review 3.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 4.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 5.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

6.  Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.

Authors:  A Molinos-Quintana; P Trujillo-Hacha; J I Piruat; J A Bejarano-García; E García-Guerrero; J A Pérez-Simón; Miguel Muñoz
Journal:  Invest New Drugs       Date:  2018-05-02       Impact factor: 3.850

7.  Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release.

Authors:  Karl Ebner; Nicolas Singewald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-19       Impact factor: 3.000

Review 8.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

9.  Ethanol inhibits the binding of substance P to rat brain cortex NK1 receptors.

Authors:  S Scarrone; A Cappelli; A Cupello; M Matarrese; R M Moresco; F Fazio
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

10.  The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

Authors:  Miguel Muñoz; Marisa Rosso
Journal:  Invest New Drugs       Date:  2009-01-17       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.